Isomorphic Labs and MSD: A New Era in Drug Development
On November 20, 2026, Isomorphic Labs, a company at the forefront of AI-driven drug design, partnered with MSD, the trading name of Merck & Co., Inc., to embark on a groundbreaking research collaboration that promises to significantly advance the field of drug discovery. This partnership aims to leverage Isomorphic Labs’ innovative artificial intelligence technologies alongside MSD’s extensive proprietary databases and years of experience in drug development.
The Collaboration’s Focus
The central goal of this collaboration is the identification of small-molecule drug candidates targeting a strategically important oncology target. Isomorphic Labs will utilize its proprietary drug design platform, IsoDDE, to generate in-silico predictions and design molecules. MSD is expected to oversee preclinical and clinical development, ensuring the manufacturing and marketing of any products resulting from this cooperative endeavor.
In accordance with their agreement, Isomorphic Labs will receive an upfront payment from MSD, along with further payments contingent upon achieving specific milestones in research, development, regulatory approval, and commercialization. Additionally, Isomorphic Labs has the option to participate in the funding of development activities in exchange for increased royalties.
Insights from the Leaders
Sarah Skerratt, Chief Research Officer at Isomorphic Labs, expressed her enthusiasm about the collaboration, stating, "Through our partnership with MSD, we will employ our globally recognized drug design platform to make significant strides in drug research. By harnessing the generative and predictive capabilities of IsoDDE for this demanding research initiative, both organizations demonstrate their shared commitment to advancing innovations that benefit patients with unmet medical needs."
George Addona, Senior Vice President and Head of Discovery, Preclinical Development, and Translational Medicine at MSD Research Laboratories, highlighted the importance of integrating experimental and computational lab work. He remarked, "The key to effectively utilizing AI and machine learning in developing new molecules lies in the seamless interplay between experimental and computational efforts. By combining MSD's extensive internal data and drug discovery expertise with Isomorphic Labs' powerful modeling and computing capabilities, we are poised to find new ways to design and develop better drug candidates more rapidly."
The Transformative Potential
This partnership exemplifies the transformative potential that emerges from the synergy of cutting-edge AI technologies, unique datasets, and established biopharmaceutical expertise. By fostering collaboration between these two influential companies, they aim to expedite the drug candidate development process and unlock complex biological systems with unprecedented speed and accuracy.
About Isomorphic Labs
Founded in 2021, Isomorphic Labs is on a mission to revolutionize drug research through artificial intelligence, heralding a new era of biomedical breakthroughs. The company is led by CEO Sir Demis Hassabis and President Max Jaderberg, with a leading modality-agnostic drug design platform, IsoDDE, based on AI foundational models. This computer-aided drug design system is designed to provide the predictive accuracy necessary to explore previously uncharted biological systems with unmatched precision.
The company is continually innovating in model architecture, developing state-of-the-art features to advance drug design further. Isomorphic Labs maintains its headquarters in London while also operating offices in Cambridge, Massachusetts, and Lausanne, Switzerland. The company is ambitious in its pursuit of drug design, engaging in both collaborative programs and wholly-owned initiatives. For more information, visit
www.isomorphiclabs.com and connect on LinkedIn and X.
About MSD
Known as Merck & Co., Inc. in the U.S. and Canada, MSD is dedicated to using cutting-edge science to save lives and improve quality of life globally. For over 130 years, MSD has provided hope through the development of critical medications and vaccines, aiming to be the world’s leading research-intensive biopharmaceutical company. Today, MSD is also pioneering research to develop innovative healthcare solutions that advance disease prevention and treatment for both humans and animals. The company promotes a diverse and inclusive workforce and is committed to responsible operations that foster a safe, sustainable, and healthy future for all communities. For more information, visit
www.msd.com and connect on X, LinkedIn, and YouTube.
This partnership between Isomorphic Labs and MSD is a testament to the future of medicine, harnessing AI to uncover new drug candidates and potentially revolutionizing the healthcare landscape.